@entity4028 -associated nephrotoxicity in XXXX .

@entity1 @entity801 @entity8 @entity3883 @entity2890 @entity648 @entity1448 @entity581 @entity4028
Experimental data demonstrate that @entity8 to @entity801 . In the present study the incidence of and risk factors for @entity4028 nephrotoxicity were prospectively studied in @entity1 with @entity3883 . Two hundred and thirty-seven hospitalized adult @entity1 were classified into three groups. Group I consisted of 84 @entity1 with @entity3883 , who received @entity4028 ( @entity801 or @entity2890 ). Group II consisted of 81 @entity1 with @entity3883 , who received either antibiotics other than @entity4028 or no antimicrobial therapy. Group III consisted of 72 noncholestatic @entity1 receiving @entity581 for different disorders. Nephrotoxicity developed in 27 @entity1 (32%) in group I vs 9 @entity1 (11%) in group II and 4 @entity1 (5.6%) in group III (p < 0.00001). In group I, a comparison of @entity1 with and without nephrotoxicity revealed significantly higher values in the former for mean serum @entity648 concentration, initial steady-state trough @entity4028 concentration and estimated half-life. Stepwise multivariate analysis with nephrotoxicity status as the dependent variable determined that the most significant variable for predicting nephrotoxicity was serum total @entity648 level. In extrahepatic @entity1448 a high serum @entity648 level is a distinct factor predisposing to @entity4028 nephrotoxicity.
